source
- Eli Lilly fronts $2 billion for vaccine biotech deals as Infinimmune secures $75 million fundingEli Lilly announced it has paid $2 billion up front as part of its ongoing strategy to acquire vaccine‑focused biotechnology companies, a portion of a larger deal that could total up to $3.8 billio…
- Ensoma cuts staff again to focus on lead gene therapy for rare immune diseaseBoston‑based biotech Ensoma announced another round of layoffs as it narrows its efforts to its sole clinical candidate, EN‑374, aimed at treating X‑linked chronic granulomatous disease (X‑CGD). E…